Genetic Variability of the mTOR Pathway and Prostate Cancer Risk in the European Prospective Investigation on Cancer (EPIC)
2011

Genetic Variability of the mTOR Pathway and Prostate Cancer Risk

Sample size: 2081 publication 10 minutes Evidence: moderate

Author Information

Author(s): Campa Daniele, Hüsing Anika, Stein Angelika, Dostal Lucie, Boeing Heiner, Pischon Tobias, Tjønneland Anne, Roswall Nina, Overvad Kim, Østergaard Jane Nautrup, Rodríguez Laudina, Sala Núria, Sánchez Maria-José, Larrañaga Nerea, Huerta José María, Barricarte Aurelio, Khaw Kay-Tee, Wareham Nicholas, Travis Ruth C., Allen Naomi E., Lagiou Pagona, Trichopoulou Antonia, Trichopoulos Dimitrios, Palli Domenico, Sieri Sabina, Tumino Rosario, Sacerdote Carlotta, van Kranen Henk, Bueno-de-Mesquita H. Bas, Hallmans Göran, Johansson Mattias, Romieu Isabelle, Jenab Mazda, Cox David G., Siddiq Afshan, Riboli Elio, Canzian Federico, Kaaks Rudolf

Primary Institution: German Cancer Research Center (DKFZ), Heidelberg, Germany

Hypothesis

Genes in the mTOR pathway and genes of the p53 pathway that directly relate to mTOR may be centrally implicated in prostate carcinogenesis.

Conclusion

The study found an association with prostate cancer risk for two SNPs in the PRKCI gene, suggesting a potential genetic influence on susceptibility to prostate cancer.

Supporting Evidence

  • Two SNPs in the PRKCI gene were associated with a decreased risk of prostate cancer.
  • The study included a total of 815 prostate cancer cases and 1,266 controls.
  • Findings were replicated in an independent population of 838 prostate cancer cases and 943 controls.
  • Statistical analysis showed significant associations at a threshold of p<0.01.
  • Results were consistent with previous studies on the mTOR pathway and cancer risk.

Takeaway

Scientists looked at genes that might affect the risk of getting prostate cancer and found two specific gene changes that could lower that risk.

Methodology

The study analyzed 1,084 tagging SNPs in 67 genes involved in the mTOR pathway in a case-control study of prostate cancer.

Potential Biases

The study did not observe major variations in allele frequencies across countries, which may mitigate bias risks.

Limitations

The study's findings may be limited by the large number of tests performed and potential confounding by population stratification.

Participant Demographics

The majority of participants were of European ('Caucasian') origin, aged 35–69.

Statistical Information

P-Value

p=0.0028 for rs4955720; p=0.0014 for rs546950

Confidence Interval

95% CI 0.76–0.94 for rs546950; 95% CI 0.78–0.93 for rs4955720

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016914

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication